Neurotech Pharma

News

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia type 2.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.